环球人寿

Globe Life Inc receives a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 4% premium over our quantitative fair value estimate of $158.41 per share; however, this estimate should be taken with a pinch of salt due to its medium uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The company's balance sheet undermines our estimated valuation. Excessive leverage heightens financial risk, potentially undermining a firm's value. For example, the firm's EBITDA/interest coverage ratio of 11.7 ranks in the bottom 50% compared with global peers. This gives us pause, as it can be a warning sign of financial distress if conditions don't improve. We believe this is a sign that shares could be expensive.

Alternatively, the company's profitability is reassuring. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 9.2%, a core component of profitability, ranks in the top 30% globally. This suggests that it is generating substantial earnings relative to its share price, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.